NASDAQ:ALGS Aligos Therapeutics Q3 2026 Earnings Results & Report $3.11 -0.84 (-21.19%) As of 03:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Aligos Therapeutics beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$2.09 versus the -$2.28 consensus estimate, while revenue of $2.87 million fell short of the $4.85 million estimate by $1.98 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 6, 2026TimeBefore Market OpensConference Call8:00 AM ET Aligos Therapeutics EPS ResultsActual EPS-$2.09Consensus EPS -$2.28Beat/MissBeat by +$0.19One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersAligos Therapeutics Revenue ResultsActual Revenue$2.87 millionExpected Revenue$4.85 millionBeat/MissMissed by -$1.98 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aligos Therapeutics Q3 2026 Earnings FAQ Did Aligos Therapeutics beat earnings estimates for Q3 2026? Aligos Therapeutics (NASDAQ:ALGS) reported earnings of -$2.09 per share for Q3 2026, beating the consensus estimate of -$2.28. The report was announced on Friday, November 6, 2026. What was Aligos Therapeutics' revenue for Q3 2026? Aligos Therapeutics reported revenue of $2.87 million for Q3 2026, against a consensus estimate of $4.85 million. Aligos Therapeutics Earnings HeadlinesAligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial ResultsNovember 6, 2026 | globenewswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Has Consensus Price Target of $38.50 According to BrokeragesNovember 6, 2026 | americanbankingnews.comMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 10 at 1:00 AM | Behind the Markets (Ad)Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026November 5, 2026 | globenewswire.comAligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting 2026October 6, 2026 | marketscreener.comMAligos Therapeutics To Present HBV, HDV Programs At AASLD 2026October 6, 2026 | rttnews.comSee More Aligos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email. Email Address About Aligos TherapeuticsAligos Therapeutics (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections. Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH. The company has also pursued antiviral programs targeting SARS-CoV-2 and other viral diseases. These products remain investigational and have not necessarily been approved for commercial use. Founded in 2018 and headquartered in South San Francisco, California, Aligos conducts research and clinical-development activities through collaborations and trials in the United States and other international markets. Its work is focused primarily on advancing proprietary small-molecule medicines from discovery through clinical development.View Aligos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
